BioCentury | Oct 17, 2013
Distillery Techniques

Technology: Drug platforms

...work includes testing the modified GLP-1 peptide in animal models of diabetes and metabolic syndrome. Arisaph Pharmaceuticals Inc....
...Published online Oct. 17, 2013 Patented by the Tufts University School of Medicine; licensed to Arisaph...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Cancer

...6(20); doi:10.1038/scibx.2013.487 Published online May 23, 2013 Covered by issued and filed patents; licensed to Arisaph Pharmaceuticals Inc....
BioCentury | Dec 10, 2012
Clinical News

ARI-3037MO: Phase I data

...Heart Association meeting in Los Angeles. ARI-3037MO is in Phase II testing for the indication. Arisaph Pharmaceuticals Inc....
BioCentury | Mar 28, 2011
Clinical News

ARI-3037MO: Phase I start

...This month, Arisaph will begin a placebo-controlled, dose-escalation Phase I trial to evaluate a single dose...
...I trial to evaluate a single dose of once-daily ARI-3037MO in about 40 healthy volunteers. Arisaph...
...said it plans to start a multiple ascending-dose Phase Ib trial of ARI-3037MO in 3Q11. Arisaph Pharmaceuticals Inc....
BioCentury | Nov 11, 2010
Distillery Therapeutics

Indication: Cancer

...control. Next steps could include animal studies of oral APOA1 mimetics to treat ovarian cancer. Arisaph Pharmaceuticals Inc.'s...
BioCentury | Nov 8, 2010
Finance

Wanted: Less Dilution

...Raised at least Wellstat Group (A) $3.5 16 ND Immunomedics Inc. (NASDAQ:IMMU) $2.9 12 $171.5 Arisaph Pharmaceuticals Inc....
BioCentury | Oct 2, 2008
Cover Story

Truly Boronic

...The findings challenge the long-held assumption that boronic acids are too toxic for therapeutic use. Arisaph Pharmaceuticals Inc....
...potent-inhibitors of DPP-4, according to William Bachovchin, leader of the Tufts team and CSO of Arisaph...
...diabetes, cancer and atherosclerosis and has out-licensed them to Arisaph . Companies and Institutions Mentioned Arisaph Pharmaceuticals Inc....
BioCentury | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

...DPP-4 inhibitors. Follow-up work has already identified another dipeptide boronic acid in this class that Arisaph Pharmaceuticals Inc....
...to treat type 2 diabetes. Inhibitors covered by international patents for diabetes treatment; licensed to Arisaph...
BioCentury | Mar 17, 2008
Clinical News

ARI-2243: Phase I start

...This half, Arisaph will begin a dose-escalation Phase I trial of oral ARI-2243 given once daily...
...begin a dose-escalation Phase I trial of oral ARI-2243 given once daily in healthy volunteers. Arisaph Pharmaceuticals Inc....
BioCentury | Aug 27, 2007
Strategy

Targeting DPP-4

...of Probiodrug's DPP-4 assets] Ph IIa (start Ph IIb early 08) Roche R1579 Ph I Arisaph...
Items per page:
1 - 10 of 16
BioCentury | Oct 17, 2013
Distillery Techniques

Technology: Drug platforms

...work includes testing the modified GLP-1 peptide in animal models of diabetes and metabolic syndrome. Arisaph Pharmaceuticals Inc....
...Published online Oct. 17, 2013 Patented by the Tufts University School of Medicine; licensed to Arisaph...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Cancer

...6(20); doi:10.1038/scibx.2013.487 Published online May 23, 2013 Covered by issued and filed patents; licensed to Arisaph Pharmaceuticals Inc....
BioCentury | Dec 10, 2012
Clinical News

ARI-3037MO: Phase I data

...Heart Association meeting in Los Angeles. ARI-3037MO is in Phase II testing for the indication. Arisaph Pharmaceuticals Inc....
BioCentury | Mar 28, 2011
Clinical News

ARI-3037MO: Phase I start

...This month, Arisaph will begin a placebo-controlled, dose-escalation Phase I trial to evaluate a single dose...
...I trial to evaluate a single dose of once-daily ARI-3037MO in about 40 healthy volunteers. Arisaph...
...said it plans to start a multiple ascending-dose Phase Ib trial of ARI-3037MO in 3Q11. Arisaph Pharmaceuticals Inc....
BioCentury | Nov 11, 2010
Distillery Therapeutics

Indication: Cancer

...control. Next steps could include animal studies of oral APOA1 mimetics to treat ovarian cancer. Arisaph Pharmaceuticals Inc.'s...
BioCentury | Nov 8, 2010
Finance

Wanted: Less Dilution

...Raised at least Wellstat Group (A) $3.5 16 ND Immunomedics Inc. (NASDAQ:IMMU) $2.9 12 $171.5 Arisaph Pharmaceuticals Inc....
BioCentury | Oct 2, 2008
Cover Story

Truly Boronic

...The findings challenge the long-held assumption that boronic acids are too toxic for therapeutic use. Arisaph Pharmaceuticals Inc....
...potent-inhibitors of DPP-4, according to William Bachovchin, leader of the Tufts team and CSO of Arisaph...
...diabetes, cancer and atherosclerosis and has out-licensed them to Arisaph . Companies and Institutions Mentioned Arisaph Pharmaceuticals Inc....
BioCentury | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

...DPP-4 inhibitors. Follow-up work has already identified another dipeptide boronic acid in this class that Arisaph Pharmaceuticals Inc....
...to treat type 2 diabetes. Inhibitors covered by international patents for diabetes treatment; licensed to Arisaph...
BioCentury | Mar 17, 2008
Clinical News

ARI-2243: Phase I start

...This half, Arisaph will begin a dose-escalation Phase I trial of oral ARI-2243 given once daily...
...begin a dose-escalation Phase I trial of oral ARI-2243 given once daily in healthy volunteers. Arisaph Pharmaceuticals Inc....
BioCentury | Aug 27, 2007
Strategy

Targeting DPP-4

...of Probiodrug's DPP-4 assets] Ph IIa (start Ph IIb early 08) Roche R1579 Ph I Arisaph...
Items per page:
1 - 10 of 16